Sabesp’s 8.24% post-earnings plunge on twice-normal volume is a warning that privatization gains are being swallowed by the cost of universalization. Adjusted EBITDA rose 26%, but that operating improvement is not enough when management is accelerating a multibillion-real investment cycle and earnings are still missing expectations. At $4.59, SBS looks statistically cheap, yet the market is correctly asking whether reported profit will ever become shareholder cash flow. Our take is firmly bearish: this is a capex trap, not a clean privatization rerating.
The broader growth profile also fails to justify treating SBS as a straightforward bargain. Revenue grew only 3.3% year over year, while EPS fell 13.7% and net income declined 13.4%. The TickerSpark Score captures that split clearly: Valuation is an exceptional 96 and Profitability is 95, but Growth is only 25 and Momentum is 30. That combination describes a profitable company whose low multiple reflects deteriorating earnings momentum and heavy reinvestment demands, not a market simply overlooking a hidden compounder.
Valuation is the other powerful counterpoint: SBS trades at just 2.23 times trailing earnings and 0.37 times book value, with a 2.9% dividend yield. Those figures leave considerable room for a rerating if cash conversion improves. Still, cheap assets can remain cheap while the investment cycle is consuming capital. Sabesp’s 26% EBITDA growth has not prevented a recent EPS miss, a 1-for-8 beat record, or a leverage ramp. The timeline for universalization may be attractive, but the near- to medium-term timing mismatch still belongs to the bears.
For SBS, the levels and signals to respect are the latest $4.59 close, the 52-week low of $4.48, and an RSI of 23.07. Oversold technicals can produce a bounce, but the distribution trend, price below the 50-day and 200-day averages, and seven recent insider sells totaling $443,077 with no insider buys do not create a durable reversal case. We would keep exposure small rather than chase the dip. The trigger that would change this view is a lower-than-expected R$20 billion capex run rate, clear evidence that free cash flow is absorbing the buildout, or leverage stabilizing as EBITDA grows; until then, the privatization story remains trapped behind its own spending plan.
Our take, not advice. This is opinion commentary — informational only, not personalized investment recommendations. Markets carry risk. Do your own research and consider your own situation before any trade.
